Home › Waldenstrom Macroglobulinemia › Washington
Waldenstrom Macroglobulinemia clinical trials in Washington
7 studies for Waldenstrom Macroglobulinemia are looking for participants at sites in Washington.
Cities in Washington
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Fred Hutchinson Cancer Research Center, Seattle
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Swedish Medical Center-First Hill, Seattle
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04840602Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Medical Oncology Associates (Summit Cancer Centers) ( Site 2710), Spokane
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04728893A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- Swedish Cancer Institute (SCI), Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328A Study of ARC-02 in B-cell NHL
- Summit Cancer Centers - North Spokane, Spokane
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07691606Study of SGR-1505 in Mature B-Cell Neoplasms
- Fred Hutchinson Cancer Center, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- Swedish Cancer Institute, Seattle
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2025 · NCT05780034From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.